85 results
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
7 May 24
Ocular Therapeutix™ Reports First Quarter 2024 Results
4:10pm
Strategy
BEDFORD, MA, May 07, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a biopharmaceutical company … forward to sharing an update on the progress of the study, along with a review of Ocular’s corporate strategy, during our Investor Day, planned
8-K
OCUL
Ocular Therapeutix Inc
18 Apr 24
Departure of Directors or Certain Officers
4:12pm
served as President of IVERIC bio, Inc., a biopharmaceutical company, from May 2021 to October 2023, and as Executive Vice President, Chief Strategy
S-3ASR
sxueqagd
25 Mar 24
Automatic shelf registration
4:40pm
8-K
EX-99.1
l2tgjy54i v06ttve
11 Mar 24
Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2023 Results
4:10pm
8-K
v9qlxfc1f4tn
22 Feb 24
Ocular Therapeutix, Inc. Announces $325.0 Million Private Placement
7:34am
424B5
jbl 3fvkh52xznp
14 Dec 23
Prospectus supplement for primary offering
4:09pm
424B5
ebwxfv5g
13 Dec 23
Prospectus supplement for primary offering
4:10pm
8-K
EX-99.1
mv8d1t 1afnm4
7 Aug 23
Ocular Therapeutix™ Provides Second Quarter 2023 Financial Results and Corporate Update
4:06pm
8-K
EX-99.1
5uam xhicyr1
8 May 23
Ocular Therapeutix™ Provides First Quarter 2023 Financial Results and Corporate Update
4:04pm